- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Study reveals Psilocybin may be more cost-effective than current treatments for depression

A new study published by Cambridge University Press has found that psilocybin combined with therapy could be more cost-effective at treating major depression disorders than currently used methods.

The study, Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model found that when psilocybin was costed at £1200 and combined with therapy from one therapist, the cost of treatment was £5239.

Psilocybin-based treatment was also found to provide stronger returns in terms of the quality of life of patients following treatment, with psilocybin’s treatment returning a QALY nearly 10% larger than the next most effective treatment, CBT.

The results come at a time when figures uncovered by the BBC found more than a quarter of patients on antidepressants in England – about two million people – have been taking them for five years. Eight million people in England are on antidepressants – a one million rise from five years previously.

The study has been authored by academics in the economics and psychedelics space, including Professor Paul McCrone of the University of Greenwich, neuropsychopharmacologist David Nutt, and Henry Fisher and Clare Knight, who both work for the commercial clinical research organisation Clerkenwell Health.

Dr Henry Fisher, Chief Scientific Officer at Clerkenwell Health, said: “With rising numbers of people in the UK prescribed anti-depressants and increasing chronic use, it’s clear the need for innovative treatments for depression has never been more pressing. Our research finds that there is great potential for psilocybin to be a cost-effective therapy for severe depression – with higher quality impacts for the individuals and society.

“We’re calling on health professionals and policymakers to seriously consider these findings which suggest psilocybin could be genuinely ground-breaking for the NHS and for the millions of people being treated for depression in the UK.”

Professor Paul McCrone, Professor of Healthcare Economics at University of Greenwich, said: “While this is a relatively expensive treatment option, the improved outcomes that seem to be achieved may justify this extra cost especially as there are few treatment options for those with the hardest to treat forms of depression. More research is needed, especially on the level of therapist support that is required, but this is an interesting therapy and could well be positioned alongside more conventional treatments.”

Professor David Nutt, Professor of Neuropsychopharmacology at Imperial College London, said: “Drug Science is very happy to have contributed our expertise to this important study. In light of the current unmet mental health needs, new treatments are urgently required. Our studies at Imperial College London (as well as research globally) indicate psilocybin to be an effective treatment for severe depression. The current study now shows that psilocybin also has the potential to be a cost-effective therapy for this condition. This of course is vital in order to progress psilocybin assisted therapy as viable treatment in public healthcare.”

- Advertisement -
Emma Cooper
Emma Cooper
Emma is Content Manager at Pf Media.


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription